Preclinical activity of MCLA-128, an ADCC enhanced bispecific IgG1 antibody targeting the HER2: HER3 heterodimer

被引：8
|
作者：
Geuijen, Cecile
Rovers, Eric
Nijhuis, Roy
den Blanken-Smit, Renate
Visser, Therese
Bartelink, Willem
Kramer, Arjen
Zondag-van der Zande, Vanessa
Clements, Carina
Kaldenberg, Linda
Nieuwenhuizen, Nellie
van Loo, Pieter Fokko
Roovers, Rob
Gallenne, Tristan
Price, Leo
Shamsili, Setareh Van Driel
Bakker, Lex
Logtenberg, Ton
de Kruif, John
Throsby, Mark
机构：
[1] Merus, Utrecht, Netherlands
[2] OcellO, Leiden, Netherlands
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.560
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
560
引用
收藏
页数：1
相关论文
共 50 条
  • [11] A phase II basket study of MCLA-128, a bispecific antibody targeting the HER3 pathway, in NRG1 fusion-positive advanced solid tumors.
    Schram, Alison M.
    Drilon, Alexander E.
    Macarulla, Teresa
    O'Reilly, Eileen Mary
    Rodon, Jordi
    Wolpin, Brian M.
    Ou, Sai-Hong Ignatius
    Kim, Dong-Wan
    Yang, James C.
    Lam, Justina Yick Ching
    Varga, Andrea
    De Langen, Joop
    Witteveen, Petronella
    Boni, Valentina
    Cerea, Giulio
    Duruisseaux, Michael
    Liu, Stephen, V
    Wasserman, Ernesto
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [12] A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3
    Rau, Alexander
    Kocher, Katharina
    Rommel, Mirjam
    Kuehl, Lennart
    Albrecht, Maximilian
    Gotthard, Hannes
    Aschmoneit, Nadine
    Noll, Bettina
    Olayioye, Monilola A.
    Kontermann, Roland E.
    Seifert, Oliver
    MABS, 2021, 13 (01)
  • [13] FDA approves first HER2 x HER3 bispecific antibody
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2025, 24 (02) : 83 - 83
  • [14] Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+metastatic gastric/gastroesophageal junction cancer (GC/GEJ)
    Alsina, M.
    Varga, A.
    Amatu, A.
    Schellens, J. H. M.
    Witteveen, P. O.
    Boni, V.
    Moreno, V.
    Bol, K.
    Lourbakos, A.
    Ferrer, M. Magin
    Wasserman, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [15] A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
    Zong, Hui-fang
    Li, Xi
    Han, Lei
    Wang, Lei
    Liu, Jun-jun
    Yue, Ya-li
    Chen, Jie
    Ke, Yong
    Jiang, Hua
    Xie, Yue-qing
    Zhang, Bao-hong
    Zhu, Jian-wei
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (08) : 1727 - 1739
  • [16] The binding mode of the bispecific anti-HER2xHER3 antibody MCLA-128 is responsible for its potent inhibition of HRG-driven tumorigenesis
    Maussang-Detaille, David
    de Nardis, Camilla
    Hendriks, Linda
    Bartelink-Clements, Carina
    Rovers, Eric
    Gallenne, Tristan
    Doornbos, Robert
    Bakker, Lex
    de Kruif, John
    Logtenberg, Ton
    Gros, Piet
    Geuijen, Cecile
    Throsby, Mark
    CANCER RESEARCH, 2017, 77
  • [17] MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer.
    Zhang, Bo
    Lahdenranta, Johanna
    Du, Jinyan
    Kirouac, Daniel
    Stephanie Nguyen
    Overland, Ryan
    Paragas, Violette
    Kudla, Arthur
    Nielsen, Ulrik
    McDonagh, Charlotte
    Onsum, Matthew
    CANCER RESEARCH, 2013, 73 (08)
  • [18] GE-huMab-HER3, a novel humanized, glycoengineered HER3 antibody with enhanced ADCC and superior preclinical in vitro and in vivo efficacy
    Bossenmaier, Birgit
    Friess, Thomas
    Gerdes, Christian
    Kolm, Irene
    Dimoudis, Nikolaos
    Lifke, Valeria
    Reiff, Ulrike
    Moessner, Ekkehard
    HoelzIwimmer, Gabriele
    von Hirschheydt, Thomas
    Burtscher, Helmut
    Niederfellner, Gerhard
    CANCER RESEARCH, 2012, 72
  • [19] Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade
    Geuijen, Cecile A. W.
    De Nardis, Camilla
    Maussang, David
    Rovers, Eric
    Gallenne, Tristan
    Hendriks, Linda J. A.
    Visser, Therese
    Nijhuis, Roy
    Logtenberg, Ton
    de Kruif, John
    Gros, Piet
    Throsby, Mark
    CANCER CELL, 2018, 33 (05) : 922 - +
  • [20] HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
    Wang, Dongsheng
    Qian, Guoqing
    Zhang, Hongzheng
    Magliocca, Kelly R.
    Nannapaneni, Sreenivas
    Amin, A. R. M. Ruhul
    Rossi, Michael
    Patel, Mihir
    El-Deiry, Mark
    Wadsworth, J. Trad
    Chen, Zhengjia
    Khuri, Fadlo R.
    Shin, Dong M.
    Saba, Nabil F.
    Chen, Zhuo G.
    CLINICAL CANCER RESEARCH, 2017, 23 (03) : 677 - 686
12345